



FFG
Forschung wirkt.

**Call Topics for International Cooperation
in Horizon 2020
EU and Thailand**

20.09.2019

Content

- Industrial Leadership** 3
 - Leadership in enabling and industrial technologies (LEIT)..... 3

- Societal Challenges** 6
 - Health, demographic change and wellbeing..... 6
 - Food security, sustainable agriculture and forestry, marine and maritime and inland water research..... 13

Impressum | Medieninhaberin und Herausgeberin:
Österreichische Forschungsförderungsgesellschaft mbH Tel.: +43 (0)5 77 55 - 0
Sensengasse 1, A - 1090 Wien Fax: +43 (0)5 7755 - 97011
FN: 252263a, Handelsgericht Wien email: office@ffg.at

Industrial Leadership

Horizon 2020 Pillar:	Industrial Leadership
Programme:	Leadership in enabling and industrial technologies (LEIT)
Call Title:	Competitive, low carbon and circular industries
Call Identifier:	h2020-low-carbon-circular-industries-2020
Topic Title:	ERA-NET on materials, supporting the circular economy and Sustainable Development Goals
Topic Identifier:	CE-NMBP-41-2020
Type of Action:	ERA-NET-Cofund ERA-NET Cofund
Deadline(s):	05.02.2020 (single-stage)

Participant Portal Weblink:

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/ce-nmbp-41-2020>

Specific Challenges: Maintaining Europe's position in research related to materials science and engineering requires concentrated action on common European research priorities in view of implementing joint initiatives.

The M-ERA.NET 2 network has successfully targeted the Low Carbon Energy Technologies addressed by the SET Plan. Now the scope should on one hand guarantee some continuation, and on the other hand become more ambitious and underline the commitment of the EU regarding the circular economy and Sustainable Development Goals.

The European Commission has adopted an ambitious new Circular Economy Package to help European businesses and consumers to make the transition to a stronger and more circular economy. Moreover, in 2016, the 17 Sustainable Development Goals (SDGs) of the 2030 Agenda for Sustainable Development came into force. They aim to end poverty, protect the planet, ensure prosperity and tackle climate change. The EU is fully committed to be a frontrunner in implementing the 2030 Agenda and SDGs. Finally, the Commission launched the Battery Alliance initiative in 2017.

Materials research is a relevant field for addressing these overall challenges and for making substantial contributions to achieving the specific objectives.

Global challenges call for co-operation on a global scale to build capacity in science, technology and innovation (STI) at both national and international levels. A strategic and industrially relevant approach is needed that cover the entire research and innovation chain by pooling national research and innovation capacities, thereby mobilising European infrastructure networks as well as promoting education and training in materials research and innovation.

Scope: The proposed ERA-NET aims at coordinating the research efforts of the participating Member States, Associated States and Regions in the field of materials, continuing the activities started by M-ERA.NET, for materials research and innovation, especially targeting the circular economy and Sustainable Development Goals (such as Goal 7 – “Affordable and clean energy”, by enabling electromobility through sustainable energy storage technology or Goal 9 “Industrial innovation and infrastructure”, by enhancing scientific research and upgrading the technological capabilities of industrial sectors). Proposals should pool the necessary financial resources from participating national or regional research programmes by implementing a joint transnational call for proposals (resulting mainly in grants to third parties) with EU co-funding to fund multinational innovative research initiatives in this domain, including support to the large scale research initiative on future battery technologies launched under the H2020-LC-BAT-2019-2020 Call^[4].

Proposers are also requested to implement other joint activities and, additional joint calls without EU co-funding. The proposal should demonstrate that these additional joint calls exclude any overlaps with related on-going actions co-funded by the EU under NMBP.

Proposals should demonstrate the expected impact on national and transnational programmes as well as the leverage effect on European research and competitiveness, and should plan the development of key indicators for supporting this.

Participation of legal entities from **third countries**, and/or regions including those not automatically eligible for funding in accordance with General Annex A is encouraged in the joint call as well as in other joint activities including additional joint calls without EU co-funding. Participants from countries not listed in General Annex A are eligible for EU funding under this topic and may request a Union contribution (on the basis of the ERA-NET unit cost) only for the coordination costs of additional activities.

The Commission considers that proposals requesting a contribution from the EU of EUR 15 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts. EUR 5 million of the requested contribution from the EU should be used as support to transnational projects, co-funded by the Commission, on future battery technologies, fostering synergy between European, national and regional initiatives and promoting broader partnerships between the European stakeholders in future battery technologies.

Expected Impact:

- synergies with international, national and regional programmes that support research and innovation;
- synergies but no overlap with the topics of Horizon 2020 and with related European Partnership initiatives and be open to adapt to future coming initiatives of Horizon Europe;
- leverage of national, regional and European funding;
- contribution to meeting Global Challenges through Better Governance: International Co-operation in Science, Technology and Innovation;

- relevant contribution to the SDGs, including sustainable battery based energy storage technology;
- relevant contribution towards a circular economy.

Cross-cutting Priorities: ERA-NET

[1] http://ec.europa.eu/research/participants/data/ref/h2020/wp/2018-2020/main/h2020-wp1820-cc-activities_en.pdf

Societal Challenges

Horizon 2020 Pillar:	Societal Challenges
Programme:	Health, demographic change and wellbeing
Call Title:	Better Health and care, economic growth and sustainable health systems
Call Identifier:	h2020-sc1-bhc-2018-2020
Topic Title:	Global Alliance for Chronic Diseases (GACD) - Prevention and/or early diagnosis of cancer
Topic Identifier:	SC1-BHC-17-2020
Type of Action:	RIA Research and Innovation action
Deadline(s):	07.04.2020 (single-stage)

Participant Portal Weblink:

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-bhc-17-2020>

Specific Challenges: The **Global Alliance for Chronic Diseases**^[1] (GACD) call will focus on implementation research proposals for the prevention^[2] and/or early diagnosis of cancer in Low and Middle-Income Countries (LMIC) and/or in vulnerable populations^[3] in High- Income Countries (HIC)^[4].

The world is facing a critical healthcare problem due to ageing societies, unhealthy lifestyles, socio-economic inequalities, and a growing world population. Cancer is becoming one of the most important public health problems worldwide. In 2018, it is estimated that 181 million^[5] people have been diagnosed with cancer and 9.6 million have died from it. Predictions suggest that 30 million people will die from cancer each year by 2030, of which three-quarters in low- and middle-income countries (LMICs).

With an estimated 30-50% of avoidable cancers, it is a leading cause of premature death, reducing a country's productivity. Current cancer prevention and control do not fully reflect ethnic, cultural, environmental, socio-economic and resource differences. In particular, limited implementation research is conducted on cancers primarily found in LMICs and vulnerable populations in HIC. In order to achieve the United Nations' sustainable development goal 3.4^[6], implementation research and healthcare efforts are needed to prevent and control cancers in these countries and populations.

Scope: Proposals should focus on implementation research for the prevention and/or early diagnosis of cancer on in LMIC and/or in vulnerable populations in HIC. Proposals should build on interventions with promising or proven effectiveness (including cost-effectiveness) for the respective population groups under defined

contextual circumstances. For promising interventions, a limited validation period can be envisaged. However, the core of the research activities should focus on their implementation in real-life settings. The proposed interventions should be gender-responsive.

The aim should be to adapt and/or upscale the implementation of these intervention(s) in accessible, affordable and equitable ways in order to improve the prevention and early diagnosis of cancer in real-life settings. Interventions should meet conditions and requirements of the local health and social system context and address any other contextual factors identified as possible barriers.

Each proposal should:

Focus on implementation research addressing prevention, and/or early identification strategies derived from existing knowledge about effective and/or promising interventions.

For screening interventions, the pathway to referral for positive cases should be included.

Include a strategy to test the proposed model of intervention and to address the socioeconomic and contextual factors of relevance to the targeted region and community.

Lead to better understanding of key barriers and facilitators at local, national and international level that affect the prevention and/or early diagnosis of cancer.

Include health economics assessments as an integral part of the proposed research, including considerations of scalability and equity.

Propose a pathway to embed the intervention into local, regional or national health policy and practice, addressing:

A strategy to include policy makers and local authorities (possibly by being part of the consortium), as well as other relevant stakeholders such as community groups, patient groups, formal and informal carers and any other group, wherever relevant from the beginning of the project, which will contribute to the sustainability of the intervention, after the end of project.

Relevance of project outcomes/evidence for scaling up the intervention at local, national and international level and then scaled-up appropriateness with respect to the local social, cultural and economic context.

Research under GACD involves regular exchange of research findings and information across participating projects by means of cross-project working groups and annual joint meetings. Wherever feasible, projects should harmonise and standardise their data collection and exchange data. Applicants must budget for annual costs of having two team members participate in one annual face-to-face meeting of the Annual Scientific Meeting (location to vary annually). Applicants must budget their involvement in GACD working groups and other GACD wide activities, beyond their projects.

The Commission considers that proposals requesting a contribution from the EU of between EUR 1 to 3 million would allow this specific challenge to be addressed

appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact: The proposals should address one of or combinations of:

- Advance local, regional or national cancer prevention and/or early diagnostic health policies, alleviating the global burden of cancer;
- Establish the contextual effectiveness of cancer intervention(s), including at health systems level;
- Improve tailored and affordable prevention and/or early diagnosis;
- Provide evidence and recommendations to national programmes and policies focusing on prevention, screening, and/or early diagnosis;
- Inform health service providers, policy and decision makers on effective scaling up of cancer interventions at local, regional, and national levels, including affordability aspects for users and health providers;
- Reduce health inequalities and inequities, including due consideration of socio-economic, gender and age issues where relevant, in the prevention and/or early diagnosis of cancer at both local and global levels;
- Provide pathway to cancer care for the patients diagnosed with cancer;
- Maximise the use of existing relevant programmes and platforms (e.g. research, data, and delivery platforms);
- Contribute to the United Nations' Sustainable Development Goal 3.4.

Cross-cutting Priorities: International cooperation, Socio-economic science and humanities

[1] <http://www.gacd.org/>

[2] Tertiary prevention is excluded from the topic.

[3] Proposals should demonstrate the vulnerability of the targeted population in HIC.

[4] <https://databank.worldbank.org/data/download/site-content/CLASS.xls>

[5] GLOBOCAN and CONCORD-3

[6] <https://www.un.org/sustainabledevelopment/health/>

Horizon 2020 Pillar: Societal Challenges

Programme: Health, demographic change and wellbeing

Call Title: Better Health and care, economic growth and sustainable health systems

Call Identifier: h2020-sc1-bhc-2018-2020

Topic Title: Actions in support of the International Consortium for Personalised Medicine

Topic Identifier: SC1-HCO-01-2018-2019-2020

Type of Action: CSA Coordination and support action

Deadline(s): 07.04.2020 (single-stage)

Participant Portal Weblink:

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-hco-01-2018-2019-2020>

Specific Challenges: Personalised Medicine is a very broad and multifaceted area where success relies on a well-functioning collaboration between several disciplines and different actors. While great advances have been made in some fields of medicine, in particular in stratification of cancer patients and in addressing rare diseases, most of today's healthcare protocols do not include personalised approaches apart from occasional division into broad age groups (children/adults/elderly), sex or ethnicity. Furthermore the prevention aspect of personalised medicine, i.e. identifying individuals prone to develop certain diseases, is largely isolated from treatment options. As is the case for a relatively nascent field there is a need for standardisation of approaches, including for sampling, data storage, interpretation and data exchange and also for clinical trials design and reimbursement models. European countries with their social model of healthcare along with (in several cases) centralised cost reimbursement, are ideally placed to lead the way for an integrated health management system. Many needs for coordination and support activities have been identified by ICPeMed^[1], an EU Member States led initiative which includes representatives from most EU countries along with several other European countries, Brazil and Canada. The EC currently supports ICPeMed with a grant to operate its secretariat until October 2020^[2]. Wider internationalisation of ICPeMed can be underpinned by coordinating networking activities with **third countries**.

Scope: Each action should focus on one of the following fields:

- **International aspect:** The action should focus on building links with **third countries** by analysing the potential and advantages of collaboration in personalised medicine (PM) with those countries, studying areas of interest for Europe in PM collaboration and promoting international standards in the field. In particular the uptake of personalised approaches in health systems and healthcare should be addressed, taking into account social, cultural, ethical and legal aspects, health economy issues and equitable healthcare. For the 2018 call, the project should focus on CELAC^[3] as a group of countries, and for the 2019 call on China. For the 2020 call, the project should focus on countries in Africa^[4], linking also into the EU-AU (African Union) policy dialogue and taking into account the new Africa-Europa Alliance for Sustainable investment and Jobs^[5]. Alignment with activities of the **Global Alliance for Chronic Diseases** (GACD) and The European and Developing Countries Clinical Trials Partnership (EDCTP) activities should be explored. Special attention should be given to prediction and prevention, and to promoting well-being for all at all ages. Furthermore, the project should seek to integrate local knowledge and practice. Data safety and privacy should be addressed in line with existing standards and legislation. The project should have a duration of at least four years and address sustainability beyond that to ensure longer term structuring effect. Due to the specific challenge of this topic, in addition to the minimum number of participants set out in the General Annexes, proposals shall include at least one participant based in the international partner region; Africa (2020 call).
- **Regional aspect:** The action should establish and support networking between regions and interregional cooperation in different European countries, in particular linking remote or sparsely populated regions with regions harbouring critical mass of medical and PM expertise while taking into account broader socio-economic and cultural aspects. The focus of the action can include aspects of genomic analysis, me-Health (mobile and electronic Health), telemedicine etc. but should aim at structuring PM application at regional level. Linkage to existing inter-regional projects (financed by INTERREG programmes) or interregional partnerships of Thematic Smart Specialisation Platforms will be actively encouraged. (2018 call).
- **Healthcare- and pharma-economic models for personalised medicine,** interlinking European public health approaches with medical practice and financing. The action should carry out studies in support of research in and development of new health- and pharma economic models for PM, including prevention, to capture value and to develop relevant health financing models. Analysing mid- and long-term impacts of innovative products designated for sub-sets of patient populations on the patients themselves and on public health systems. Assessing the benefits of personalised medicine development for citizens and their broader social environment while ensuring patient safety, access, equity, solidarity, data safety and financial sustainability of public health systems in the EU. The action should involve different relevant stakeholders and take into account work being carried out by other EU funded initiatives, such as EUnetHTA^[6]. SME participation is encouraged. Results of the studies and workshops should be actively disseminated to a wider

audience, including relevant authorities, professionals and the wider public. (2018 call).

- Standardisation for clinical study design. Establishment of innovative clinical trial design methodology for PM, including guidelines for research and reflection papers. The action should take into account sex/gender differences as well as the work done by relevant stakeholders and authorities such as EMA^[7] and the HMA network^[8], as well as the European legal framework^[9]. SME participation is encouraged. The results of the studies and workshops should be actively disseminated to a wider audience, including, industry, researchers and other professionals. (2019 call).
- ICPeMed secretariat: The project should continue the work done by the secretariat for ICPeMed, e.g. maintenance of existing services, organising the meetings of the ICPeMed Executive Committee, convening dedicated workshops and preparing and issuing updates of the ICPeMed Action Plan. Furthermore maintaining the network of policy makers and funders gathered in ICPeMed and expanding the membership to new interested and complementary partners as well as maintaining communication with all EC funded activities related to ICPeMed (2020 call).

For grants awarded under this topic for Coordination and Support Actions it is expected that results could contribute to European or international standards. Therefore, the respective option of Article 28.2 of the Model Grant Agreement will be applied.

The Commission considers that proposals requesting a contribution from the EU of between EUR 1.5 and 2 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact: Contributing to the implementation and reach of the ICPeMed initiative; furthermore:

- International aspect: Integrating the country/group of countries into ICPeMed activities. Support wider adoption of standards developed in Europe. Support the EU-AU policy dialogues relevant to research and health (2020 call). Contribute towards the UN Sustainable Development Goal 3: Ensure healthy lives and promote well-being for all at all ages.
- Regional aspect: Strengthened links between European regions setting up or planning personalised medicine healthcare approaches. Aligning research funding with ongoing and foreseen investments e.g. from Structural Funds. Recommendations on best practice in implementing PM at regional level.
- Healthcare- and pharma-economic models: Increased understanding of personalised medicine perspectives on how to capture value, develop institutional support and design relevant payment models. Recommendations for faster translation from discovery to patients'/citizens' access. Contributing to understanding of trends and dynamics in the pharmaceutical markets in relation to increased emphasis of research and development efforts on PM. Suggestions on how savings through prevention can be included in payment and reward models and contribute to the sustainability of public health

systems in the EU. Improved knowledge and understanding among healthcare professionals and the wider public of potential benefits of PM approaches.

- Standardisation for clinical study design: Contribute to standardisation of PM clinical trial design. Demonstrate feasibility and importance of PM approaches. Underpin accelerated market uptake. Improved knowledge and understanding among healthcare professionals, regulatory authorities and industry how best to adapt clinical trials designs to stratified patient populations.
- ICPeMed secretariat (2020 Call): Ensure continuity of the operations of ICPeMed beyond 2020. Increase the visibility of the consortium and ensure openness of the structure. Provide harmonised vision for the further development of personalised medicine. Contribute to the convergence of members' approaches to personalised medicine and further alignment of research efforts in the field.

Cross-cutting Priorities: Gender, International cooperation, Socio-economic science and humanities

[1] <http://icpermed.eu>

[2] H2020 Grant Agreement 731366

[3] Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominica, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Grenada, Guyana, Jamaica, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Lucia, Saint Kitts and Nevis, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela

[4] African Union Member States

[5] <https://www.africa-eu-partnership.org/en/stay-informed/news/european-commission-unveils-new-africa-europe-alliance-sustainable-investment-and>

[6] European Network for Health Technology Assessment: <http://www.eunetha.eu/>

[7] European Medicines Agency: <https://www.ema.europa.eu>

[8] Heads of Medicines Agencies: <http://www.hma.eu/>

[9] Especially the clinical trials regulation (EU) No 536/2014 and the data protection regulation (EU) 2016/679

Horizon 2020 Pillar:	Societal Challenges
Programme:	Food security, sustainable agriculture and forestry, marine and maritime and inland water research
Call Title:	Sustainable Food Security
Call Identifier:	h2020-sfs-2018-2020
Topic Title:	Healthy terrestrial livestock microbial ecosystems for sustainable production
Topic Identifier:	SFS-02-2020
Type of Action:	RIA Research and Innovation action
Deadline(s):	22.01.2020, 08.09.2020 (two-stage)

Participant Portal Weblink:

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sfs-02-2020>

Specific Challenges: Research is increasingly paying attention to the importance of interactions between the animal host and microbiota and their effects on the production efficiency, and the health and welfare of animals. These interactions are highly dynamic and influenced not only by genetics, but also by external factors such as environment, nutrition/feeding and management. Recent developments in omics science and technologies have opened new avenues for understanding not only the biology and genetics of animals, but also the ecosystems in which they function and those which they harbour, i.e. microbiomes. This is particularly relevant for micro-organisms that are currently non-culturable. Research on the interplay between the animals and their microbial ecosystems is needed to contribute to the improvement of sustainable livestock production.

Scope: Activities shall address relevant microbial ecosystems of terrestrial livestock, and their effects on the production, health and welfare of animals. They should look in a balanced way at the characterisation of microbial ecosystems (including microbial communities and microbe-derived metabolites), assessing variability within and between breeds in relation to variability of production systems and diet; at microbial behaviour (e.g. interactions between microbiota, evolution with age of animals, transmission); at microbial functions and interactions with host, environment and management practices, including feeding where relevant; and at possible ways in which those ecosystems can be managed, including socio-economic aspects, in order to reduce environmental impact, improve production and its quality, and/or health in particular during challenging periods

such as early life, weaning or after disturbances. Activities will include the incorporation of data on microbial ecosystems in the models used to analyse phenotypic variability and to perform genetic evaluations. The activities shall address either ruminants, or monogastrics. Gut microbiome of pigs or poultry can be addressed only in so far as the activities are complementary to those in related projects selected under LC-SFS-03-2018. Proposals may cover one or more species and one or more microbial ecosystem.

Research on anti-microbial resistance can be included as long as it is not the main objective of the project (see topic SFS-12-2018/2019). Research on single animal pathogens is not the focus of the topic. The projects are encouraged to interact as appropriate with relevant collaborative projects in Europe as appropriate and with international initiatives such as the rumen microbial genomics network of the **Global Research Alliance on Agricultural Greenhouse Gases**^[1].

The Commission considers that proposals requesting a contribution from the EU of up to EUR 10 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts. Funding will allow support for at least one project relating to ruminants and one to monogastrics.

Expected Impact: Funded activities will contribute to deciphering the characteristics and functions of the livestock microbial ecosystems and understand the ways in which they influence production, health and/or welfare of animals. They will provide standardised methodologies for further application in livestock production to the greatest extent possible, including socio-economic aspects.

In the short- to medium term, the application of the knowledge and solutions developed will, as appropriate:

- enable inclusion of data on microbial ecosystems in the models used to analyse phenotypic variability and to perform genetic evaluations;
- improve resource use and environmental impact of terrestrial livestock production;
- improve robustness and health of terrestrial livestock, in relation to productive functions;
- reinforce collaborations with initiatives in related domains to promote coherence and applicability of research on microbial ecosystems.

In the longer term, the funded activities will contribute to more resilient production systems.

Delegation Exception Footnote: This topic is part of a microbiome cluster. For complementary activities see also SC2 topics SFS-01-2018/19/20, SFS-03-2018 and BG-06-2018 on Marine Microbiomes as SC1 topic SC1-BHC-03-2018

Cross-cutting Priorities: International cooperation

^[1] <https://globalresearchalliance.org/research/livestock/networks/rumen-microbial-genomics-network>